Generics - Pharmaceutical, Research

Filter

Current filters:

PharmaceuticalResearch

Popular Filters

1 to 25 of 39 results

Teva to drop development of Nuvigil in bipolar 1 disorder

31-08-2013

Israel-based leading generics company Teva Pharmaceutical Industries (NYSE: TEVA) has released disappointing…

armodafinilCephalonGenericsNeurologicalNuvigilPharmaceuticalResearchTeva Pharmaceutical Industries

Pharmstandard commits $30 million to Argos Therapeutics; post 1st-half results

28-08-2013

Russia's largest drugmaker Pharmstandard (PHST: RU) that its subsidiary Pharmstandard International.(Luxembourg)…

AGS-003Argos TherapeuticsFinancialGenericsOncologyPharmaceuticalPharmstandardResearch

BPH drug doesn't increase risk of death, but does save men from prostate cancer

15-08-2013

A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research…

finasterideGenericsMen's HealthMerck & CoOncologyPharmaceuticalProscarResearch

New lab hopes to attract Western pharma for preclinical studies in Russia

09-08-2013

One of Russia's largest laboratories for preclinical studies of drugs will soon be opened in the Vsevologsk…

Dom of PharmacyEuropeGenericsPharmaceuticalResearch

Eternity and PharmaNova to develop branded medicines

18-07-2013

Canadian medical device company Eternity Healthcare (OTC:ETAH) has signed a letter of intent with privately-held…

Eternity HealthcareGenericsMetabolicsPharmaceuticalPharmaNovaResearch

Indian pharma threatened by trend of shifting R&D operations overseas: survey

04-07-2013

Red tape is putting India's multi-billion dollar worth pharmaceutical industry at risk, with most of…

Asia-PacificGenericsMarkets & MarketingPharmaceuticalRegulationResearch

Generics triple-therapy just as effective as brand-name Enbrel, new study shows

13-06-2013

Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…

AmgenAnti-Arthritics/RheumaticsEnbrelGenericsmethotrexatePharmaceuticalResearch

GlaxoSmithKline and A*STAR's ICES to develop medicines for emerging markets

09-04-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and Singapore-based A*STAR's Institute of Chemical and Engineering…

GenericsGlaxoSmithKlineGlobalPharmaceuticalResearch

Indian Pharma growth outpaces rivals, but must embrace innovation

12-03-2013

Ranking among the top five globally by production volume, the Indian pharmaceutical market at present…

Asia-PacificBiotechnologyGenericsMarkets & MarketingPharmaceuticalProductionResearch

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

25-02-2013

Belgium drug developer Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with…

AblynxGenericsidebenoneIdecortexLicensingMarkets & MarketingNeurologicalOncologyPharmaceuticalResearchSolent PharmaSpirogen

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study

10-02-2013

Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

ScinoPharm and Foresee Pharma set up JV for novel oncological peptide drugs

31-01-2013

Taiwanese drugmaker ScinoPharm (TWSE: 1789) and Foresee Pharmaceuticals, a Delaware, USA-based spin-out…

Asia-PacificForesee PharmaceuticalsGenericsleuprolideOncologyPharmaceuticalProductionResearchScinoPharm

Japan Pharma: Expectations for 2013, by P Reed Maurer

03-01-2013

The biggest non-event in the Japan health care market during 2013 will be no reimbursement price reductions,…

Asia-PacificGenericsLicensingMergers & AcquisitionsPharmaceuticalPricingResearch

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Major constraints in the hospital-treated infections drug market include generic erosion

06-12-2012

The hospital-treated infections (HTI) drug market, the loss of patent protection for key branded products…

Antibiotics and Infectious diseasesGenericsGlobalMarkets & MarketingPharmaceuticalResearch

Migraine drug sales to grow to $5.8 billion in 2021 in major markets

18-11-2012

Despite a decline in sales owing to the generic entry of most triptans, the launch of emerging acute…

AllerganBotoxCoLucidGenericsGloballasmiditanLevadexMAP PharmaceuticalsMarkets & MarketingPharmaceuticalResearch

European Parliament starts clinical trial talks; EGA chief resigns

15-11-2012

The European Parliament is about to start discussions regarding Clinical Trials that are vital to get…

EuropeGenericsManagementPharmaceuticalRegulationResearch

Australian Pharma sees opportunities in govt "Asian Century" report

30-10-2012

The government's Australia in the Asian Century report, released this week, highlights the opportunity…

Asia-PacificGenericsMarkets & MarketingPharmaceuticalProductionResearch

EMA expects lower rate of generic applications; Issues guidelines on schizophrenia and MS

11-10-2012

In its mid-year report for 2012, the European Medicines Agency's management board yesterday provided…

BiotechnologyEuropeGenericsNeurologicalPharmaceuticalRegulationResearch

Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan

10-09-2012

SFJ Pharmaceuticals Group, a global drug development group of companies which provides a unique co-development…

dacomitinibDetrol LAGastro-intestinalsGenericsLegalMylan LaboratoriesNorth AmericaOncologyPatentsPfizerPharmaceuticalResearchSFJ Pharmaceuticals

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute

10-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies…

Asia-PacificAstraZenecaCiplaErlocipGenericsMetabolicsOncologyPalatin TechnologiesPatentsPharmaceuticalResearchRocheTarceva

1 to 25 of 39 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top